Investors

Press Releases

Date Title View
Toggle Summary Momenta Pharmaceuticals Announces District Court Decision to Invalidate Teva Pharmaceuticals Patents in COPAXONE® (glatiramer acetate injection) 40 mg/mL Litigation
Four of Teva's Orange-Book listed patents ruled invalid due to obviousness
View HTML
Toggle Summary Momenta Provides Year-End 2016 Corporate Update
-- New collaboration and license agreement with CSL to develop Fc multimer programs, including M230, with a $50M upfront license fee -- -- Agreement with Shire to receive full rights to M923 and a $51M one-time return payment -- CAMBRIDGE, Mass. , Jan.
View HTML
Toggle Summary Momenta and CSL Announce Collaboration and License Agreement to Develop Fc Multimer Programs, Including M230, a Selective Immunomodulator of Fc Receptors
--Momenta to receive $50 million upfront license fee and up to $550 million in potential milestone payments from CSL--              --Momenta to host a conference call for its investors today at 4:30 PM ET -- CAMBRIDGE, Mass. , Jan. 05, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc.
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the 35th Annual J. P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Jan. 03, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Craig Wheeler , President and CEO, will present at the 35th Annual J. P.
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Positive Top-Line Phase 3 Results for M923, a Proposed HUMIRA® (adalimumab) Biosimilar
CAMBRIDGE, Mass. , Nov. 29, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that the confirmatory Phase 3 clinical study of M923, a biosimilar HUMIRA ® (adalimumab) candidate developed in collaboration with Baxalta, now part of Shire plc, in patients with
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Publication on the Design of M230, a Novel Autoimmune Disease Drug Candidate, in Science Translational Medicine
Data show M230's ability to block immune complex-mediated damage and robust efficacy in preclinical
View HTML
Toggle Summary Momenta Pharmaceuticals Appoints Scott M. Storer as Senior Vice President and Chief Financial Officer
CAMBRIDGE, Mass. , Nov. 02, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Scott M. Storer as Senior Vice President and Chief Financial Officer.
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Third Quarter 2016 Financial Results
--Company appoints Scott M. Storer as SVP and CFO-- --Initiates Phase 1 trial for M834, biosimilar ORENCIA ® (abatacept) candidate-- CAMBRIDGE, Mass. , Nov. 02, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the third quarter ended
View HTML
Toggle Summary Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)
Advancement of M834 to clinical-stage development represents important milestone in the Momenta/Mylan biosimilar portfolio
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast at Two Upcoming Investor Conferences
CAMBRIDGE, Mass. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
View HTML